Randox Covid Test Centre Opens at Belfast City Airport
Randox Covid Test Centre Opens at Belfast City Airport
Randox has today opened a new Covid-19 testing facility with Belfast City Airport.
The test centre, purpose-built by leading Belfast building firm H&J Martin, offers quick and affordable PCR and antigen (lateral flow) tests, with its opening coinciding with the resumption of international flights from Belfast City Airport.
Airport Operations Manager, Judith Davis, explained:
“Flights have resumed today from Belfast City to Amsterdam Schiphol Airport with our airline partner KLM, which is another positive step as airlines across the world rebuild and restart their networks.
“Currently the Dutch Government requires all passengers entering the Netherlands to have taken and returned a negative result from both a PCR and an antigen (lateral flow) test. Providing this service on-site is the ultimate convenience for our passengers, which is something we pride ourselves on and continually strive to enhance.”
PCR tests by Randox at Belfast City Airport are available at the reduced price of £85, with antigen tests available for £45. Judith details further the benefits this offers the people of Northern Ireland;
“These tests, which must be pre-booked, aren’t just reserved for passengers flying from Belfast City Airport but are also available for non-flying members of the general public.
“The fact that results from the antigen tests are returned within one hour, and a digital ‘safe to fly’ certificate is issued directly to the passenger’s mobile device, is also another huge bonus and adds a further layer of convenience for our customers who need to travel.”
Speaking of the partnership with Belfast City Airport, and the importance of this test facility at the UK and Ireland’s most convenient airport, Project Manager at Randox, Sophie Boyd, said:
“Randox are committed to supporting those wishing to undertake international travel, including holidays, and the travel industry. In doing so we believe we will be improving wellbeing and supporting employment.
“As flights resume and we open the Randox Health Travel Centre at Belfast City Airport we will provide competitive, effective and efficient testing to support the travelling public.
“We are delighted to be working in partnership with Belfast City Airport and wish them every success in re-establishing their international travel links.”
(l-r John McConnell of H&J Martin, Judith Davis, Airport Operations Manager, and Sophie Boyd, Project Manager at Randox)
This Covid-19 testing facility is the latest health and safety measure to be implemented at Belfast City Airport, which was the first airport in Northern Ireland to achieve the ACI’s Airport Health Accreditation for its extensive, thorough, and best-in-class passenger safety procedures.
“The wellbeing of our passengers and staff remains of paramount importance to us and those travelling to the airport can be reassured that stringent measures are in place for their safety,” Judith concluded.
Covid-19 testing at the Airport is available by appointment only and slots can be booked now at https://booking.randox.com/
For further information on Covid testing at Belfast City Airport please contact the Randox Covid Customer Support team on covidcustomersupport@randox.com or 0800 2545 201.
For press enquiries please contact Amy Millar in the Randox PR team on amy.millar@randox.com or 028 9442 2413
Want to know more?
Contact us or visit the Randox Health Travel Centre booking page
Related COVID-19 Products and Services
HOME TEST
ANTIBODY TEST
TEST TO RELEASE
LABORATORY TOOLS
SARS-CoV-2 (COVID-19) Antigen Testing Pilot Study from Randox Quality Control
SARS-CoV-2 (COVID-19) Antigen Testing Pilot Study
12 March 2020
SARS-CoV-2 (COVID-19) Antigen Testing Pilot Study
Randox, in partnership with QCMD, is pleased to announce a new QCMD EQA pilot study for SARS-CoV-2 (COVID-19) Antigen Testing. This new pilot is designed to evaluate a laboratory’s ability to detect SARS-CoV-2 (COVID-19) antigen and will provide an opportunity to assess performance against an international peer group.
QCMD is a world leading EQA / Proficiency Testing (PT) provider, dedicated to improving the quality of molecular diagnostic assays used in the detection of infectious diseases. With an extensive database of over 2000 participants in over 100 countries, QCMD is one of the largest providers of molecular EQA in the fi eld of infectious disease testing.
Features & Benefits
-
Whole PathogenAvailability of whole pathogen samples containing the entire viral genome, ensures commutability with the majority of commercial assays.
-
Smart-Phone App Results SubmissionResults can be returned via a smart-phone app so that participants using lateral flow devices can provide pictures of their device/result with the phone camera.
-
Comprehensive ReportsA real-time rapid report will be provided on submission of results. An individual report is received after each challenge, summarising laboratory performance in comparison to an international peer group.
-
EQA Management SystemIT EQA Management System (ITEMS) provides an online tool to easily manage all EQA activities from programme registration to submission of results and provision of EQA reports.
-
Not infectiousSamples containing SARS-CoV-2 antigens are inactivated and not infectious ensuring safe handling of material.
-
Suitable for Point of CareSamples are supplied liquid ready-to-use ensuring they are ideal for use at the point care.
For more information visit https://www.randox.com/qcmd-sars-antigen-testing/
For further enquiries please email marketing@randox.com
QCMD
QNOSTICS
CORONAVIRUS
COVID-19 Testing: PCR (Diagnostic) vs Antibody
18 June 2020
COVID-19 Testing: PCR (Diagnostic) vs Antibody
The advice from the World Health Organisation in relation to the COVID-19 pandemic has been simple; Test. Test. Test.
But what are the different types of COVID-19 tests and what are they used for?
Diagnostic (PCR) Testing
This type of testing detects SARS-CoV-2 (the virus that causes COVID-19) within the body and will tell you if you currently have COVID-19. PCR tests cannot tell you if you have had past infection.
Sample collection for a PCR test can vary, though it is usually in the form of a swab, which will gather an individual’s nasopharyngeal (nose and throat) secretions.
PCR tests for COVID-19 all use methods that detect a specific part of the viral genome – for example Viral RNA or Antigen.
A sample is prepared by extracting the chosen section of the genome, and then PCR (Polyamerase Chain Reaction) techniques are used to amplify (replicate) the genome section, ready for detection.
Viral RNA Tests
This type of test detects the RNA (Ribonucleic acid) contained within the SARS-CoV-2 virus.
It is this type of test, for RNA, that is recommended by The World Health Organisation for COVID-19 diagnosis.
Antigen Tests
Antigens are molecular structures on the surface of viruses that are recognized by the immune system and are capable of triggering an immune response.
Antigen tests detect the presence of the SARS-CoV-2 virus by looking for the antigen on the surface of the virus.
Randox COVID-19 Test
The Randox COVID-19 test, as recommended by the World Health Organisation, detects the RNA contained within the SARS-CoV-2 virus.
After sample extraction and amplification, the virus is detected on our patented Randox Biochip Technology platform.
The Randox Biochip, which can run multiple tests simultaneously, performs two tests for COVID-19 – one specific and one confirmatory – as recommended by the WHO. This delivers extra assurance of the correct diagnosis and avoids the need to repeat the test.
Antibody (Serology) Tests
Antibody (also known as serology) tests, are usually performed on a patient blood sample, and look for antibodies (a type of protein) that may have been developed by the patient’s immune system to fight off disease.
If present, antibodies may provide a degree of immunity for the patient against COVID-19 in the future.
However, there is still much unknown about the body’s antibody response to COVID-19, including;
- Whether all patients who have been infected with SARS-CoV-2 will generate antibodies (recent studies and news reports indicate that this isn’t the case. Click here for an example.)
- Whether those who have had more severe symptoms as a result of COVID-19 will produce more antibodies than those who had mild symptoms, or were asymptomatic.
- If antibodies from other coronaviruses previously experienced by the patient may be enough to fight off the virus, therefore eliminating the need for COVID-19 specific antibodies.
- How long any COVID-19 specific antibody response will last for.
- How much future immunity is provided by COVID-19 antibodies. Will it prevent the patient from being infected, or will future infection just be less severe?
If antibodies for the SARS-CoV-2 virus are present this can give an indication that the patient has been previously infected with COVID-19. Antibody tests do not confirm the real-time presence of the virus in your system.
For example, a negative antibody result does not necessarily mean the body has not been exposed to the SARS-CoV-2 virus. It could in fact, be currently infected, but has not yet generated antibodies. A diagnostic test will confirm current presence of the virus.
Therefore, it is recommended that antibody tests are used in tandem with a diagnostic test to determine a complete overview of the patient’s COVID-19 status.
Randox Health currently offers both diagnostic testing and antibody testing for SARS-CoV-2 (COVID-19).
A combination of diagnostic and antibody testing is available for individual purchase, or as part of our ‘Back to Business’ COVID-19 testing service, for staff screening.
Visit Randox Health to find out more.
Want to know more about Randox?
Contact us or visit our homepage to view more.